

Lien Nguyen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11378810/publications.pdf>

Version: 2024-02-01

14
papers

653
citations

759233

12
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

709
citing authors

#	ARTICLE	IF	CITATIONS
1	RAN proteins in neurodegenerative disease: Repeating themes and unifying therapeutic strategies. <i>Current Opinion in Neurobiology</i> , 2022, 72, 160-170.	4.2	10
2	The alternative initiation factor eIF2A plays key role in RAN translation of myotonic dystrophy type 2 CCUGâ€¢CAGG repeats. <i>Human Molecular Genetics</i> , 2021, 30, 1020-1029.	2.9	17
3	Repeat length increases disease penetrance and severity in <i>C9orf72</i> ALS/FTD BAC transgenic mice. <i>Human Molecular Genetics</i> , 2021, 29, 3900-3918.	2.9	7
4	Antibody Therapy Targeting RAN Proteins Rescues C9 ALS/FTD Phenotypes in C9orf72 Mouse Model. <i>Neuron</i> , 2020, 105, 645-662.e11.	8.1	70
5	Survival and Motor Phenotypes in FVB C9-500 ALS/FTD BAC Transgenic Mice Reproduced by Multiple Labs. <i>Neuron</i> , 2020, 108, 784-796.e3.	8.1	22
6	Metformin inhibits RAN translation through PKR pathway and mitigates disease in <i>C9orf72</i> ALS/FTD mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18591-18599.	7.1	79
7	Repeat-Associated Non-ATG Translation: Molecular Mechanisms and Contribution to Neurological Disease. <i>Annual Review of Neuroscience</i> , 2019, 42, 227-247.	10.7	62
8	A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a <i>Drosophila</i> Model of Myotonic Dystrophy. <i>ChemMedChem</i> , 2016, 11, 1428-1435.	3.2	36
9	Integrating Display and Delivery Functionality with a Cell Penetrating Peptide Mimic as a Scaffold for Intracellular Multivalent Multitargeting. <i>Journal of the American Chemical Society</i> , 2016, 138, 9498-9507.	13.7	26
10	Rationally Designed Small Molecules That Target Both the DNA and RNA Causing Myotonic Dystrophy Type 1. <i>Journal of the American Chemical Society</i> , 2015, 137, 14180-14189.	13.7	106
11	Targeting Toxic RNAs that Cause Myotonic Dystrophy Type 1 (DM1) with a Bisamidinium Inhibitor. <i>Journal of the American Chemical Society</i> , 2014, 136, 6355-6361.	13.7	91
12	Small Molecules that Target the Toxic RNA in Myotonic Dystrophy Typeâ€¢2. <i>ChemMedChem</i> , 2014, 9, 2455-2462.	3.2	21
13	Developing Bivalent Ligands to Target CUG Triplet Repeats, the Causative Agent of Myotonic Dystrophy Type 1. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9471-9481.	6.4	51
14	A Novel CUG^{exp}-MBNL1 Inhibitor with Therapeutic Potential for Myotonic Dystrophy Type 1. <i>ACS Chemical Biology</i> , 2013, 8, 1037-1043.	3.4	54